4.4 Article

Cerebrospinal fluid diversion and outcomes for lung cancer patients with leptomeningeal carcinomatosis

期刊

ACTA NEUROCHIRURGICA
卷 164, 期 2, 页码 459-467

出版社

SPRINGER WIEN
DOI: 10.1007/s00701-021-04763-w

关键词

Leptomeningeal carcinomatosis; Shunt; Hydrocephalus; Lung cancer; Brain metastasis; EGFR mutation

向作者/读者索取更多资源

CSF diversion (VP or LP shunt) is an effective and safe treatment for lung cancer patients with LMC and hydrocephalus, potentially increasing overall survival and improving quality of life. Programmable shunts should be considered for complex cases to allow for pressure adjustments as the disease progresses.
Objective To investigate the outcomes of cerebrospinal fluid (CSF) diversion in lung cancer patients with leptomeningeal carcinomatosis (LMC). Methods A retrospective review of consecutive lung cancer patients with LMC suffering from increased intracranial pressure (IICP) and hydrocephalus between February 2017 and February 2020. We evaluated the survival benefit of CSF diversion surgery and assessed the outcomes of treatments administered post-LMC in terms of overall survival and shunt-related complications. Results The study cohort included 50 patients (median age: 59 years). Ventricular peritoneal (VP) shunts were placed in 33 patients, and lumbar peritoneal (LP) shunts were placed in 7 patients. Programmable shunts were placed in 36 patients. Shunt adjustment was performed in 19 patients. Kaplan-Meier analysis revealed that shunt placement increased overall survival from 1.95 months to 6.21 months (p = 0.0012) and increased Karnofsky Performance Scores (KPS) from 60 to 70. Univariate analysis revealed no difference between VP or LP shunts in terms of survival. No differences in post-shunt systemic treatments (tyrosine kinase inhibitors (TKIs) or systemic treatments) were observed in overall survival. Shunt-related complications were noted in 7 patients, including shunt obstruction (n = 4), infection (n = 1), and over-drainage (n = 2). Conclusion CSF diversion (VP or LP shunt) appears to be an effective and safe treatment for lung cancer patients with LMC and hydrocephalus. Programmable shunts should be considered for complex cases, which commonly require pressure adjustments as the disease progresses.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据